Characteristics and outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–PSMA-617 (PSMA-RLT) in a real-world setting.

Autor:	Kersting, David, Kim, Moon-Sung, Puellen, Lukas, Seidl-Rathkopf, Kathi, Schinwald, Nicole, Mpofu, Philani, Altomare, Ivy, Sujenthiran, Arun, Royce, Trevor Joseph, Buhl, Christoph, Grünwald, Viktor, Herrmann, Ken, Kleesiek, Jens, Hadaschik, Boris A.
Zdroj:	Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p143-143, 235p
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu